ArticleFrontiers in allergy2026
Multi-targeted protection of Yuping Tongqiao against allergic rhinitis: suppression of inflammatory response via TSLP signaling and reinforcement of epithelial barrier integrity via AhR signaling.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic rhinitis (AR) is a prevalent chronic inflammatory disorder characterized by persistent inflammation and nasal epithelial barrier disruption. Restoring epithelial integrity and modulating the inflammatory cascade are considered promising therapeutic strategies for AR. Purpose: This study aims to systematically investigate the therapeutic efficacy of Yuping Tongqiao Tablet (YPTQ), a traditional Chinese medicine formula, in the treatment of AR and to decipher its potential mechanisms and active ingredients focusing on inflammation amelioration and barrier restoration. Methods: An AR model was established in Sprague-Dawley rats that were sensitized and challenged with OVA. After intervention with different doses of YPTQ, nasal pathological injury and inflammatory cell infiltration were evaluated. Results: In the OVA-induced AR rat model, YPTQ effectively alleviated nasal symptoms, reduced histopathological damage and inflammatory cell infiltration, and suppressed overall inflammatory levels. In the HDM-induced RPMI-2650 cell injury model, YPTQ significantly inhibited inflammatory cytokines release and upregulated the tight junction protein ZO-1, thereby enhancing epithelial barrier function. Moreover, integrated analysis combining network pharmacology, molecular docking, and both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.